Ginsenoside Rh4 Triggers Ferroptosis in Lung Cancer: Targeting KEAP1/NRF2/HO-1 and Remodeling Gut Microbiota for Butyrate-Mediated ATF3 Activation
Open Access
- 16 March 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2703
Abstract
Lung cancer progression is regulated by multiple factors, including ferroptosis and gut microbiota-mediated butyrate metabolism. This study investigates the anti-tumor effects of ginsenoside Rh4 on lung cancer cells via ferroptosis mechanisms in vitro and in vivo. In vitro, ginsenoside Rh4 inhibited the proliferation of Lewis lung carcinoma (LLC) and A549 cells and triggered ferroptosis, effects that were suppressed by the ferroptosis inhibitor Ferrostatin-1 (Fer-1). In vivo, tumor-bearing mouse models were established and treated with 100 mg/kg ginsenoside Rh4 for 21 days. Tumor growth, ferroptosis markers, gut microbiota, and butyrate were analyzed, with in vitro validation of butyrate’s pathway effects. Ginsenoside Rh4 induced ferroptosis in LLC cells both in vitro and in vivo, inhibiting tumor growth. It promoted ferroptosis by disrupting iron homeostasis through elevated Fe2+ and transferrin receptor (TFRC), and impaired antioxidant defense via depletion of glutathione (GSH) and reduction in ferritin heavy chain 1 (FTH1), solute carrier family 40 member 1 (SLC40A1), solute carrier family 7 member 11 (SLC7A11), and glutathione peroxidase 4 (GPX4). Additionally, ginsenoside Rh4 enhanced lipid peroxidation, indicated by increased lipid peroxides (LPO) and malondialdehyde (MDA). In vivo, it suppressed the KEAP1/NRF2/HO-1 pathway, reducing antioxidant enzyme activity. Gut microbiota modulation and butyrate production further amplified ferroptosis by activating transcription factor 3 (ATF3)-mediated GPX4 suppression. Ginsenoside Rh4 induces ferroptosis by inhibiting the KEAP1/NRF2/HO-1 pathway and remodeling the gut microbiota to increase butyrate levels, which synergistically enhance tumor cell ferroptosis sensitivity through ATF3 activation and suppression of GPX4.Keywords
Funding Information
- Jilin Academy of Agricultural Sciences (CXGC2024ZY032)
- Department of Science and Technology of Jilin Province (YDZJ202601ZYTS552)
This publication has 43 references indexed in Scilit:
- Sodium butyrate increases USP5-mediated ubiquitination degradation of GPX4 and enhances anti-cancer efficacy of anti-PD-1 antibodyBiochemical Pharmacology, 2025
- Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalanceMolecular Oncology, 2024
- Regulation of gut microbiota on immune cell ferroptosis: A novel insight for immunotherapy against tumorCancer Letters, 2024
- Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancerFree Radical Biology and Medicine, 2024
- Lung cancer progression alters lung and gut microbiomes and lipid metabolismHeliyon, 2023
- Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinomaCellular Oncology, 2023
- Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axisApoptosis, 2023
- Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signalingMedicinal Research Reviews, 2023
- Ginsenoside Rk3 alleviates gut microbiota dysbiosis and colonic inflammation in antibiotic-treated miceFood Research International, 2021
- G-Rh4 improves pancreatic β-cells dysfunction in vivo and in vitro by increased expression of Nrf2 and its target genesFood and Chemical Toxicology, 2021